Form 8-K - Current report:
SEC Accession No. 0001104659-23-023779
Filing Date
2023-02-21
Accepted
2023-02-21 16:06:27
Documents
12
Period of Report
2023-02-21
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm237439d1_8k.htm   iXBRL 8-K 27553
  Complete submission text file 0001104659-23-023779.txt   202756

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aytu-20230221.xsd EX-101.SCH 3030
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aytu-20230221_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aytu-20230221_pre.xml EX-101.PRE 22593
6 EXTRACTED XBRL INSTANCE DOCUMENT tm237439d1_8k_htm.xml XML 3607
Mailing Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112
Business Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

EIN.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 23648097
SIC: 2834 Pharmaceutical Preparations